# China NMPA Drug Inspection - Gansu Lanyao Pharmaceutical Co., Ltd. commissioned Gansu Fuzheng Pharmaceutical Technology Co., Ltd. - Zhenqi Fuzheng Capsules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/gansu-lanyao-pharmaceutical-co-ltd-commissioned-gansu-fuzheng-pharmaceutical-technology-co-ltd/bcada1d8-a8b0-4711-b35d-870d8c1bc014/
Source feed: China

> China NMPA drug inspection for Gansu Lanyao Pharmaceutical Co., Ltd. commissioned Gansu Fuzheng Pharmaceutical Technology Co., Ltd. published February 09, 2021. Drug: Zhenqi Fuzheng Capsules. On February 9, 2021, the Beijing Municipal Drug Administration published its first drug quality and safety report for th

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Beijing Municipal Drug Administration's Announcement on the First Phase of Drug Quality and Safety Report for 2021
- Company Name: Gansu Lanyao Pharmaceutical Co., Ltd. commissioned Gansu Fuzheng Pharmaceutical Technology Co., Ltd.
- Publication Date: 2021-02-09
- Drug Name: Zhenqi Fuzheng Capsules
- Inspection Finding: Properties do not meet regulations
- Action Taken: Relevant authorities have taken necessary control measures against the substandard drugs and are investigating and dealing with the substandard products in accordance with relevant laws and regulations.
- Summary: On February 9, 2021, the Beijing Municipal Drug Administration published its first drug quality and safety report for the year, based on comprehensive sampling inspections conducted throughout 2020. The inspections, carried out by various district-level market supervision bureaus, focused on the distribution and use of pharmaceutical products across the city. The report highlighted a specific instance of non-compliance involving Zhenqi Fuzheng Capsules, batch number J20190906. The drug was manufactured by Gansu Lanyao Pharmaceutical Co., Ltd. under commission from Gansu Fuzheng Pharmaceutical Technology Co., Ltd. A sample collected from the Beijing Obstetrics and Gynecology Hospital failed quality testing conducted by the Beijing Dongcheng District Food and Drug Safety Monitoring Center. The primary violation identified was a failure to meet the 'Appearance' standards established by the Ministry of Health's Drug Standards for Traditional Chinese Medicine. This regulatory action was executed under the 'Implementation Plan for the 2020 Beijing Municipal Drug, Medical Devices, and Cosmetics Quality Sampling and Inspection Work.' Following the discovery of the substandard batch, authorities confirmed that the relevant units have initiated control measures. The non-compliant products are currently being handled in accordance with local laws and regulations to ensure public safety and maintain the integrity of the drug supply chain.

Company: https://www.globalkeysolutions.net/companies/gansu-lanyao-pharmaceutical-co-ltd-commissioned-gansu-fuzheng-pharmaceutical-technology-co-ltd/9a02f90b-5b41-4281-976c-601ae4621f60/